Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Analysis of the therapeutic potential of c-Abl inhibition in Parkinson’s disease & MSA

Milton Werner, PhD, Inhibikase Therapeutics, Inc., Atlanta, GA, discusses their significant success in modeling Parkinson’s disease and multiple system atrophy (MSA) and the therapeutic potential of c-Abl inhibition. Through studies on a mouse model, they have administered an oral c-Abl inhibitor once a day and observed the recovery of the mice, with preserved neurons and restored walking function. Furthermore, the drug has shown the ability to reduce the pathology associated with alpha-synuclein in MSA and Parkinson’s disease. By reproducing the human disease in animal models, the team aims to ensure a therapeutic benefit before proceeding to clinical trials. Their model-based approach, combined with multiple evaluations at different disease stages, provides hope for successful treatment in most patients. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Milton Werner reports the following disclosures:
Founder and largest shareholder, Inhibikase Therapeutics, Inc.